Illumina (NASDAQ:ILMN) had its price target raised by research analysts at Barclays from $200.00 to $215.00 in a research note issued on Wednesday. The firm currently has an “equal weight” rating on the life sciences company’s stock. Barclays’ target price suggests a potential downside of 7.44% from the company’s previous close.
ILMN has been the topic of several other research reports. Zacks Investment Research raised Illumina from a “hold” rating to a “buy” rating and set a $229.00 price objective on the stock in a research note on Friday, October 27th. Canaccord Genuity reissued a “buy” rating and set a $230.00 target price (up previously from $215.00) on shares of Illumina in a research note on Thursday, October 12th. Piper Jaffray Companies reissued an “overweight” rating and set a $226.00 target price (up previously from $202.00) on shares of Illumina in a research note on Monday, October 9th. Janney Montgomery Scott raised Illumina from a “sell” rating to a “neutral” rating in a research note on Monday, October 23rd. Finally, Robert W. Baird raised Illumina from a “neutral” rating to an “outperform” rating and lifted their target price for the company from $184.00 to $228.00 in a research note on Wednesday, October 25th. One research analyst has rated the stock with a sell rating, eight have given a hold rating and fifteen have issued a buy rating to the company. Illumina currently has an average rating of “Buy” and a consensus target price of $237.83.
Illumina (ILMN) traded down $8.91 during midday trading on Wednesday, hitting $232.27. The stock had a trading volume of 1,059,253 shares, compared to its average volume of 979,999. The company has a debt-to-equity ratio of 0.41, a current ratio of 4.22 and a quick ratio of 3.73. Illumina has a 1 year low of $156.50 and a 1 year high of $248.97. The company has a market capitalization of $34,230.00, a P/E ratio of 47.55, a P/E/G ratio of 3.24 and a beta of 0.79.
In other Illumina news, Director Robert S. Epstein sold 1,250 shares of Illumina stock in a transaction that occurred on Saturday, December 29th. The stock was sold at an average price of $217.38, for a total value of $271,725.00. Following the sale, the director now owns 8,838 shares of the company’s stock, valued at approximately $1,921,204.44. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Jay T. Flatley sold 20,000 shares of Illumina stock in a transaction that occurred on Tuesday, November 7th. The stock was sold at an average price of $210.59, for a total value of $4,211,800.00. Following the completion of the sale, the director now directly owns 536,717 shares in the company, valued at approximately $113,027,233.03. The disclosure for this sale can be found here. In the last ninety days, insiders sold 133,921 shares of company stock worth $29,309,093. Corporate insiders own 0.89% of the company’s stock.
Large investors have recently added to or reduced their stakes in the business. Dupont Capital Management Corp bought a new stake in Illumina in the 3rd quarter worth approximately $153,000. Mitsubishi UFJ Securities Holdings Co. Ltd. increased its stake in Illumina by 113.9% in the 4th quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 770 shares of the life sciences company’s stock worth $168,000 after acquiring an additional 410 shares during the last quarter. Advisory Services Network LLC increased its stake in Illumina by 13.0% in the 2nd quarter. Advisory Services Network LLC now owns 772 shares of the life sciences company’s stock worth $134,000 after acquiring an additional 89 shares during the last quarter. Riverbridge Partners LLC bought a new stake in Illumina in the 4th quarter worth approximately $202,000. Finally, Outfitter Advisors LTD. bought a new stake in Illumina in the 4th quarter worth approximately $205,000. 91.71% of the stock is currently owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION WARNING: “Illumina (ILMN) Price Target Raised to $215.00” was originally published by American Banking and Market News and is the property of of American Banking and Market News. If you are viewing this piece of content on another website, it was copied illegally and republished in violation of international copyright & trademark legislation. The original version of this piece of content can be accessed at https://www.americanbankingnews.com/2018/01/31/illumina-ilmn-price-target-raised-to-215-00.html.
About Illumina
Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.
